Mostrar el registro sencillo del ítem
Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study
dc.contributor.author | Alcalá Díaz, Juan Francisco | |
dc.contributor.author | Limia-Pérez, Laura | |
dc.contributor.author | Gómez-Huelgas, Ricardo | |
dc.contributor.author | Martín-Escalante, María D. | |
dc.contributor.author | Cortés Rodríguez, Begoña | |
dc.contributor.author | Zambrana-García, José L. | |
dc.contributor.author | Entrenas-Castillo, Marta | |
dc.contributor.author | Pérez-Caballero, Ana I. | |
dc.contributor.author | López-Carmona, María D. | |
dc.contributor.author | García-Alegría, Javier | |
dc.contributor.author | Lozano Rodríguez-Mancheño, Aquiles | |
dc.contributor.author | Arenas-de Larriva, María del Sol | |
dc.contributor.author | Pérez-Belmonte, Luis M. | |
dc.contributor.author | Jungreis, Irwin | |
dc.contributor.author | Bouillon, Roger | |
dc.contributor.author | Quesada Gómez, José Manuel | |
dc.contributor.author | López-Miranda, José | |
dc.date.accessioned | 2021-05-24T06:51:12Z | |
dc.date.available | 2021-05-24T06:51:12Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | http://hdl.handle.net/10396/21367 | |
dc.description.abstract | Context. Calcifediol has been proposed as a potential treatment for COVID-19 patients. Objective: To compare the administration or not of oral calcifediol on mortality risk of patients hospitalized because of COVID-19. Design: Retrospective, multicenter, open, non-randomized cohort study. Settings: Hospitalized care. Patients: Patients with laboratory-confirmed COVID-19 between 5 February and 5 May 2020 in five hospitals in the South of Spain. Intervention: Patients received calcifediol (25-hydroxyvitamin D3) treatment (0.266 mg/capsule, 2 capsules on entry and then one capsule on day 3, 7, 14, 21, and 28) or not. Main Outcome Measure: In-hospital mortality during the first 30 days after admission. Results: A total of 537 patients were hospitalized with COVID-19 (317 males (59%), median age, 70 years), and 79 (14.7%) received calcifediol treatment. Overall, in-hospital mortality during the first 30 days was 17.5%. The OR of death for patients receiving calcifediol (mortality rate of 5%) was 0.22 (95% CI, 0.08 to 0.61) compared to patients not receiving such treatment (mortality rate of 20%; p < 0.01). Patients who received calcifediol after admission were more likely than those not receiving treatment to have comorbidity and a lower rate of CURB-65 score for pneumonia severity ≥ 3 (one point for each of confusion, urea > 7 mmol/L, respiratory rate ≥ 30/min, systolic blood pressure < 90 mm Hg or diastolic blood pressure ≤ 60 mm Hg, and age ≥ 65 years), acute respiratory distress syndrome (moderate or severe), c-reactive protein, chronic kidney disease, and blood urea nitrogen. In a multivariable logistic regression model, adjusting for confounders, there were significant differences in mortality for patients receiving calcifediol compared with patients not receiving it (OR = 0.16 (95% CI 0.03 to 0.80). Conclusion: Among patients hospitalized with COVID-19, treatment with calcifediol, compared with those not receiving calcifediol, was significantly associated with lower in-hospital mortality during the first 30 days. The observational design and sample size may limit the interpretation of these findings. | es_ES |
dc.format.mimetype | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | https://creativecommons.org/licenses/by/4.0/ | es_ES |
dc.source | Nutrients 13(6), 1760 (2021) | es_ES |
dc.subject | COVID-19 | es_ES |
dc.subject | Calcifediol | es_ES |
dc.subject | SARS-CoV-2 | es_ES |
dc.subject | COVID-19 drug treatment | es_ES |
dc.subject | Vitamin D | es_ES |
dc.title | Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://dx.doi.org/10.3390/nu13061760 | es_ES |
dc.relation.projectID | Junta de Andalucía. COVID-0011-2020 | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |